Market Overview

PIRAMAL IMAGING BECOMES LIFE MOLECULAR IMAGING

Share:

PIRAMAL IMAGING BECOMES LIFE MOLECULAR IMAGING

PR Newswire

LONDON, BERLIN, BOSTON, August 27, 2018 /PRNewswire-iReach/ -- Following the recent acquisition by Alliance Medical Group, Piramal Imaging is being renamed Life Molecular Imaging ("LMI").

LMI is now part of the Alliance Medical Molecular Imaging division, an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. These combined services allow physicians, pharmaceutical industry and academia greater access to established and innovative imaging agents for clinical trials and clinical routine.

LMI will continue to offer imaging services, proprietary products and other promising investigational agents currently in clinical development that are complemented by R&D services. Neuraceq (florbetaben F18), a globally approved and commercialized product for beta-amyloid plaque imaging, can be applied in clinical routine in patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline. Neuraceq and other investigational tracers such as PI-2620 for tau imaging are also used as part of clinical trials, e.g. for AD drug development.

"Becoming Life Molecular Imaging is an exciting step for us and provides a greater opportunity to realize our vision," said Ludger Dinkelborg, Managing Director of LMI. "The new corporate structure positions us perfectly to become the preferred partner for molecular imaging agents and innovative imaging solutions. We are happy to be able to retain our core personnel and expertise within a stronger dedicated organization."

About Neuraceq™ (florbetaben 18F)

Indication and Important Safety Information

Neuraceq is a radiopharmaceutical for diagnostic use indicated for Positron Emission Tomography (PET) imaging of beta-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive impairment. Neuraceq should be used in conjunction with a clinical evaluation. A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD. For the limitations in the interpretation of a positive scan, please refer to the approved product information.

The efficacy of florbetaben (18F) for predicting development of AD or monitoring response to therapy has not been established. Neuraceq images should only be interpreted by readers trained in the interpretation of PET images with florbetaben (18F). Following training, image reading errors (including false positive or false negative interpretation of Neuraceq images) may still occur. Administration of Neuraceq, as with other radiopharmaceuticals, results in a low amount of ionizing radiation exposure and appropriate safety precautions should be taken to avoid unintentional radiation exposure. The most common side effects observed in clinical trials were injection site erythema and injection site pain.

About PI-2620

PI-2620 is an 18F-labeled investigational PET tracer that was discovered in a research collaboration between Piramal Imaging and AC Immune, a Swiss-based clinical stage biopharmaceutical company focused on neurodegenerative diseases. Life Molecular Imaging has the exclusive, world-wide license for research, development and commercialization of tau PET tracers generated within the discovery program.

About Life Molecular Imaging (LMI)

LMI (formerly Piramal Imaging) was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. By developing novel PET tracers for molecular imaging, LMI is focusing on a key field of modern medicine. LMI strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. Please visit www.life-mi.com.

About Alliance Medical

Alliance Medical, a Division of Life Healthcare Group, is Europe's leading diagnostic and molecular imaging services provider delivering high quality diagnostic solutions in partnership with public and private organisations. It provides PET/CT services at over 60 locations and operates 10 radiopharmacies producing a range of Radiopharmaceuticals for PET/CT imaging across Europe, including the National PET/CT Contract in England which provides PET/CT scans for 60% of the English population. Please visit www.alliancemedical.com.

About Life Healthcare Group

Established in 1983, The Life Healthcare Group has more than 32 years' experience in the private healthcare and hospital industry. With headquarters in Johannesburg, South Africa, the Group is a listed company on the Johannesburg Stock Exchange. The company's primary business is private acute hospital care with 64 healthcare facilities in seven of South Africa's nine provinces and one hospital in Botswana, as well as providing services for acute physical rehabilitation, mental health, renal dialysis and oncology. The Group includes an international presence through Alliance Medical Group in the UK and Europe, Scanmed S.A. in Poland and Max Healthcare in India. The three cornerstones of the Life Healthcare Group business and its commitment to patients are, Life, Health and Care. For additional information about the Group, please visit www.lifehealthcare.co.za.

Media Contact: Nicole Fletcher, Life Molecular Imaging, +1 (857) 202-1122, n.fletcher@life-mi.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Life Molecular Imaging

View Comments and Join the Discussion!